IL151906A0 - Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2 - Google Patents

Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2

Info

Publication number
IL151906A0
IL151906A0 IL15190601A IL15190601A IL151906A0 IL 151906 A0 IL151906 A0 IL 151906A0 IL 15190601 A IL15190601 A IL 15190601A IL 15190601 A IL15190601 A IL 15190601A IL 151906 A0 IL151906 A0 IL 151906A0
Authority
IL
Israel
Prior art keywords
hodgkin
lymphoma
interleukin
antibody
therapy
Prior art date
Application number
IL15190601A
Other languages
English (en)
Original Assignee
Chiron Corp
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Univ Rochester filed Critical Chiron Corp
Publication of IL151906A0 publication Critical patent/IL151906A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL15190601A 2000-03-24 2001-03-23 Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2 IL151906A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19204700P 2000-03-24 2000-03-24
PCT/US2001/009413 WO2001072333A1 (en) 2000-03-24 2001-03-23 Methods of therapy for non-hodgkin's lymphoma using a combination_of an antibody to cd20 and interleuking-2

Publications (1)

Publication Number Publication Date
IL151906A0 true IL151906A0 (en) 2003-04-10

Family

ID=22708018

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15190601A IL151906A0 (en) 2000-03-24 2001-03-23 Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2

Country Status (7)

Country Link
US (1) US20020009427A1 (ja)
EP (1) EP1267927A1 (ja)
JP (1) JP2003528155A (ja)
AU (1) AU2001247737A1 (ja)
CA (1) CA2404390A1 (ja)
IL (1) IL151906A0 (ja)
WO (1) WO2001072333A1 (ja)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2372603C (en) 1999-05-07 2015-11-17 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
DK1666052T3 (da) * 2000-02-16 2011-09-12 Genentech Inc Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050070689A1 (en) * 2001-08-03 2005-03-31 Genentech, Inc. Taci and br3 polypeptides and uses thereof
JP2005538034A (ja) * 2001-12-07 2005-12-15 カイロン コーポレイション 非ホジキンリンパ腫の治療方法
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
US8287864B2 (en) * 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
US20050043516A1 (en) * 2002-07-25 2005-02-24 Genentech, Inc. TACI antibodies and uses thereof
EP2316856B1 (en) * 2002-10-17 2017-08-09 Genmab A/S Human monoclonal antibodies against CD20
AU2011202520C1 (en) * 2002-10-17 2016-02-18 Genmab A/S Human monoclonal antibodies against CD20
AU2015205832A1 (en) * 2002-10-17 2015-08-13 Genmab A/S Human Monoclonal Antibodies Against CD20
KR20070055625A (ko) * 2002-12-16 2007-05-30 제넨테크, 인크. 이뮤노글로불린 변이체 및 이들의 용도
RU2358762C9 (ru) 2003-04-09 2016-10-10 Джинентех, Инк. Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
DK1631313T3 (en) * 2003-06-05 2015-06-15 Genentech Inc Combination therapy for b cell disorders
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
CA2564529A1 (en) * 2004-05-05 2005-12-15 Genentech, Inc. Preventing autoimmune disease
KR20150092374A (ko) * 2004-06-04 2015-08-12 제넨테크, 인크. 다발성 경화증의 치료 방법
DOP2005000108A (es) * 2004-06-04 2007-06-15 Genentech Inc Method for treating lupus
AU2005267028A1 (en) * 2004-07-22 2006-02-02 Genentech, Inc. Method of treating Sjogren's syndrome
EP1812060A2 (en) * 2004-10-05 2007-08-01 Genentech, Inc. Method for treating vasculitis
MX2007008218A (es) * 2005-01-13 2007-08-17 Genentech Inc Procedimiento de tratamiento.
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
AU2006251647A1 (en) * 2005-05-20 2006-11-30 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
CN105012953B (zh) 2005-07-25 2018-06-22 阿普泰沃研发有限责任公司 用cd37-特异性和cd20-特异性结合分子减少b-细胞
BRPI0614183A2 (pt) 2005-07-25 2011-03-15 Trubion Pharmaceuticals Inc uso de dose única de moléculas de ligação especìficas para cd20
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
RU2487888C2 (ru) 2006-06-12 2013-07-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Одноцепочечные мультивалентные связывающие белки с эффекторной функцией
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
EP2233149B1 (en) 2007-10-16 2016-02-10 ZymoGenetics, Inc. Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease
US7914785B2 (en) * 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
ATE513856T1 (de) 2008-04-11 2011-07-15 Emergent Product Dev Seattle Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon
WO2010011697A1 (en) * 2008-07-21 2010-01-28 Immunomedics Inc. Structural variants of antibodies for improved therapeutic characteristics
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
KR20200111282A (ko) 2009-08-11 2020-09-28 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
CN102050879B (zh) * 2009-10-30 2014-02-19 上海抗体药物国家工程研究中心有限公司 抗人cd20人源化抗体、其制备方法及用途
US20110145072A1 (en) * 2009-12-15 2011-06-16 Bradley John Christiansen System and Method for Producing And Displaying Content Representing A Brand Persona
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
WO2013177187A2 (en) * 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
KR102647100B1 (ko) 2015-05-30 2024-03-13 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드 및 이를 포함하는 세포-표적화 분자
CN113999312A (zh) 2015-06-24 2022-02-01 豪夫迈·罗氏有限公司 具有定制亲和力的抗转铁蛋白受体抗体
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
PE20181004A1 (es) 2015-10-02 2018-06-26 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
PL195870B1 (pl) * 1998-08-11 2007-11-30 Biogen Idec Inc Zastosowanie przeciwciała anty-CD20, zastosowanieznakowanego radioaktywnie przeciwciała anty-CD20,zastosowanie przeciwciała anty-CD20 do przygotowania leku zwierającego przeciwciało i chemioterapięoraz zastosowanie przeciwciała anty-CD20 do przygotowania leku zawierającego przeciwciało i szpik kostny

Also Published As

Publication number Publication date
CA2404390A1 (en) 2001-10-04
EP1267927A1 (en) 2003-01-02
JP2003528155A (ja) 2003-09-24
US20020009427A1 (en) 2002-01-24
AU2001247737A1 (en) 2001-10-08
WO2001072333A1 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
IL151906A0 (en) Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2
IL152896A0 (en) Cancer treatments by using a combination of an antibody against her2 and interleukin-2
IL206980A0 (en) Antibodies that bind human interleukin-18 and methods of making and using
EP1551875A4 (en) TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
PL320337A1 (en) Portable device for immediately analysing body fluids
YU28503A (sh) Humanizovana anti-lt-beta-r antitela
EP0703628A3 (en) MOSFET device with increased mobility and manufacturing method
IL143797A0 (en) Human monoclonal antibodies to cytotoxic t lymphocyte antigen 4
IL122370A (en) Monkey monoclonal antibodies to human B7 antigens and pharmaceutical compositions containing them
HUP9902327A3 (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
AP2000001983A0 (en) Antibodies to cd23 derivatives thereof and their therapeutic uses
EP1438467A4 (en) SILENCER MATERIAL FOR USE IN VEHICLES AND METHOD FOR THE PRODUCTION THEREOF
EP1011725A4 (en) HUMANIZED ANTIBODIES AGAINST GP39 HUMAN, COMPOSITIONS CONTAINING THESE ANTIBODIES AND THERAPEUTIC USE THEREOF
AU2002362098A8 (en) Methods of therapy for non-hodgkin's lymphoma
FR2813520B1 (fr) Dispositif de maintien corporel pour fauteuil verticalisateur et fauteuil en faisant application
EP1067199A4 (en) METHOD FOR COUNTING MICROORGANISMS AND DEVICE FOR PERFORMING SAID COUNT
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
AU2542295A (en) A disposable liquid-absorbent article, method and apparatus for its manufacture
LT96140A (en) The use of fibrin-specific antibody as an antithrombic agent
AU5688596A (en) Anti-cd14 antibodies for use in the induction of il-10 secre tion
GB9618945D0 (en) Device for depletion of leukocytes
GB0023654D0 (en) Device for administering doses of particulate material
AU3544599A (en) Use of radiolabeled monoclonal igm in therapy for cancer and autoimmune disease
HU0103040D0 (en) High - level source and it's application
AU2567599A (en) Anti-ccr1 antibodies and methods of use therefor